Investigation Report on China's Simvastatin Market, 2019-2023


Description
The blood lipid levels of Chinese people are rising as China's economy develops and a high-calorie and high-fat diet becomes increasingly prevalent. In 2018, the overall incidence of dyslipidemia in Chinese adults was up to about 40%. As dyslipidemia is a major cause of coronary heart disease, strokes and other atherosclerotic lesions, the treatment of hyperlipidemia can reduce the incidence of these diseases. 
Developed by U.S. company MSD, Simvastatin is a semi-synthetic HMG-CoA reductase inhibitor with Lovastatin as the raw material. It was first launched in 1988, and approved by the FDA in Dec. 1991. The trade name of MSD's Simvastatin is Zocor. Simvastatin can prevent the development of atherosclerosis and prevent the relapse of heart diseases, and reduce the risks of nonfatal myocardial infarction and myocardial revascularization. 
In 1995, MSD introduced Simvastatin to China. Simvastatin is the first widely used statin in China and the only statin that has been included in China's essential medicine list and needs to complete the consistency evaluation by 2018. And the users of Simvastatin can enjoy some preferential policies. Numerous advertisements and early launch have made Zocor well-known in community-level hospitals. In an agreement with the Chinese government, MSD promised to lower the prices of Simvastatin for a bigger market share. 
CRI's market research shows that the sales value of Simvastatin in sample hospitals in China was about CNY142 million in 2017, and is declining in the competition with other similar drugs. By sales value, China's Simvastatin market is dominated by Hangzhou MSD Pharmaceutical Co., Ltd., MSD, Guangzhou Nanxin Pharmaceutical Co., Ltd., Cinmed Pharmaceuticals, and Yangtze River Pharmaceutical Group Sichuan Hairong Pharmaceutical Co., Ltd. In 2017, the market share by sales value of Hangzhou MSD Pharmaceutical Co., Ltd. was about 63%, which means that branded Simvastatin still has great advantages on the Chinese market. 
According to CRI's estimate, Simvastatin will still have certain growth potential in China from 2019 to 2023 as the incidences of cardiovascular diseases keep increasing with the rising urbanization level, aging population and changing lifestyle.

Topics Covered:
- Development environment of statins in China
- Supply of and demand for Simvastatin in China
- Major Simvastatin manufacturers in China
- Prices of Simvastatin in China
- Prospect of China's Simvastatin market from 2019 to 2023
Table of Contents
1 Relevant Concepts of Simvastatin
1.1 Indications for Simvastatin
1.2 Development of Simvastatin in China
1.3 Governmental Approval of Simvastatin in China

2 Sales of Simvastatin in China, 2013-2017
2.1 Sales Value of Simvastatin
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Simvastatin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Simvastatin by Dosage Form in China, 2013-2017
2.3.1 Simvastatin Tablets
2.3.2 Simvastatin Capsules
2.3.3 Simvastatin Pills

3 Analysis on Major Simvastatin Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Simvastatin Manufacturers
1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Hangzhou MSD Pharmaceutical Co., Ltd. 
3.2.1 Enterprise Profile
3.2.2 Sales of Hangzhou MSD Pharmaceutical Co., Ltd.'s Simvastatin in China
3.3 MSD
3.3.1 Enterprise Profile
3.3.2 Sales of MSD's Simvastatin in China
3.4 Guangzhou Nanxin Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Guangzhou Nanxin Pharmaceutical Co., Ltd.'s Simvastatin in China
3.5 Cinmed Pharmaceuticals
3.6 Yangtze River Pharmaceutical Group Sichuan Hairong Pharmaceutical Co., Ltd. 

4 Prices of Simvastatin in China, 2017-2018
4.1 Hangzhou MSD Pharmaceutical Co., Ltd. (Zocor)
4.2 MSD (Zocor)
4.3 Guangzhou Nanxin Pharmaceutical Co., Ltd. (Simcor)
4.4 Cinmed Pharmaceuticals (Jianzhiting)
4.5 Yangtze River Pharmaceutical Group Sichuan Hairong Pharmaceutical Co., Ltd. (Xindasu)

5 Prospect of China's Simvastatin Market, 2019-2023
5.1 Major Factors Influencing Development China's Simvastatin Market
5.1.1 Favorable Factors
5.1.2 Unfavorable Factors
5.2 Forecast on Market Size of Simvastatin in China
5.3 Forecast on Market Trend of Simvastatin in China

Selected Charts
Chart Government Approval of Simvastatin in China
Chart Sales of Simvastatin in China, 2013-2017
Chart Sales Value of Simvastatin in Parts of China, 2013-2017
Chart Sales Volume of Simvastatin in China, 2013-2017
Chart Sales Volume of Simvastatin in Parts of China, 2013-2017
Chart Sales Value of Simvastatin Tablets in China, 2013-2017
Chart Sales Volume of Simvastatin Tablets in China, 2013-2017
Chart Sales Value of Simvastatin Capsules in China, 2013-2017
Chart Sales Value of Simvastatin Pills in China, 2013-2017
Chart Market Share of Top 5 Simvastatin Manufacturers by Sales Value in China, 2013-2017
Chart Sales Value of Hangzhou MSD Pharmaceutical Co., Ltd.'s Simvastatin, 2013-2017
Chart Sales Volume of Hangzhou MSD Pharmaceutical Co., Ltd.'s Simvastatin, 2013-2017
Chart Profile of MSD
Chart Sales Value of MSD's Simvastatin in China, 2013- 2017
Chart Sales Volume of MSD's Simvastatin in China, 2013- 2017
Chart Profile of Guangzhou Nanxin Pharmaceutical Co., Ltd. 
Chart Sales Value of Guangzhou Nanxin Pharmaceutical Co., Ltd.'s Simvastatin, 2013-2017 
Chart Prices of Hangzhou MSD Pharmaceutical Co., Ltd.'s Simvastatin (Zocor) in Parts of China, 2017-2018
Chart Prices of MSD's Simvastatin (Zocor) in Parts of China, 2017-2018
Chart Prices of Guangzhou Nanxin Pharmaceutical Co., Ltd.'s Simvastatin (Simcor) in Parts of China, 2017-2018
Chart Prices of Cinmed Pharmaceuticals' Simvastatin (Jianzhiting) in Parts of China, 2017-2018
Chart Forecast on Sales Value of Simvastatin in China, 2019-2023


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by China Research and Intelligence

Investigation Report on China's Finasteride Market, 2019-2023

Description The prostate is a male-specific gonadal organ. Benign prostatic hyperplasia (BPH) is the most common benign disease among the causes of urination disorder in middle-aged and elderly men. Epidemiologically, the incidence of BPH increases w...

Investigation Report on China's Prothrombin Complex Concentrate (PCC) Market, 2019-2023

Description Hemophilia is an X-linked recessive hemorrhagic disease. It is classified into hemophilia A, a deficiency in clotting factor VIII and hemophilia B, a deficiency in clotting factor IX. Both hemophilia A and hemophilia B are caused by gene ...

Investigation Report on China's Recombinant Human Thrombopoietin Market, 2019-2023

Description In recent years, the incidence of thrombopenia in China keeps increasing. Thrombopenia is often seen in hematologic diseases such as primary immune thrombopenia, leukemia and aplastic anemia as well as in connective tissue diseases, liver...

Investigation Report on China's Pegaspargase Market, 2019-2023

Description According to the data released by China?s National Health Commission in Oct. 2018, the incidence of childhood leukemia in Chinese children under 15 is about 4/100,000 to 5/100,000, and the number of childhood leukemia patients under 18 ol...

Investigation Report on China's Basiliximab Market, 2019-2023

Description In China, 10.80% or about 150 million people have chronic kidney disease, and over 3 million of them have end-stage renal disease, i.e. uremia. According to CRI, the incidence of chronic kidney disease in China stays at a high level in re...

New Pharmaceuticals and Healthcare Reports

Publisher: China Research and Intelligence